From Awareness to Action: International Men’s Health Week and Cancer Screening

This year, from 10 to 16 June we celebrate the International Men’s Health Week. The dates are different each year, so it precedes and includes Father’s Day. Multiple activities around the world aim to raise awareness of men’s preventable health problems and early detection (1).

The official framework was created in 1994 and got to an international level in 2002 when representatives from six men’s health organizations around the world met at the 2nd World Congress on Men’s Health in Vienna, Austria (2).

More than 10 million men are diagnosed with cancer each year, if we extrapolate recent data from . If non-melanoma skin cancer cases are excluded, the cancers of lung, prostate and colorectum are the most frequent (3). 

We briefly list below some of the screening recommendations for these types of cancer. It is important to mention that before getting the screening tests, the potential benefits and drawbacks have to be discussed with the healthcare provider.

Prostate Cancer

  • Age 50 for men at average risk of prostate cancer who are expected to live at least 10 more years
  • Age 45 for men at high risk of prostate cancer, including all Black men and any man with a father or brother diagnosed with prostate cancer before age 65
  • Age 40 for men at even higher risk, including any men with more than one brother or both a father and brother who had prostate cancer, and men who carry any BRCA gene mutations

Prostate-specific antigen (PSA) is the main screening test, but a digital rectal exam (DRE) may also be done as a part of screening. 

Colorectal Cancer

Screening can be done either with stool-based tests (fecal immunochemical test, Guaiac-based fecal occult blood test or Stool DNA test), or with visual exams of the colon and rectum (colonoscopy, CT colonography or flexible sigmoidoscopy). If any of the other tests mentioned above (except for colonoscopy) have an abnormal result, the person should also get a colonoscopy.

  • Everyone should start regular screening at age 45.
  • People who are in good health and with a life expectancy of more than 10 years should continue regular colorectal cancer screening through age 75.
  • For people ages 76 to 85, the decision to be screened should be based on a person’s preferences, life expectancy, health, and screening history.
  • People over age 85 should no longer get colorectal cancer screening.

Lung Cancer

  • Are ages 50 to 80 years and smoke or used to smoke and
  • Have at least a 20 pack-year history of smoking (a pack-year is the equivalent amount of cigarettes as smoking 1 pack of cigarettes per day for a year)

Yearly low-dose thorax CT scan is the main screening method in this case (4).

As we celebrate International Men’s Health Week and reflect on the strides made in healthcare, MVision AI remains steadfast in its support for healthcare providers. Together, let’s continue to prioritize health and strive for a future where everyone can access the care they deserve.

References:

  1. https://menshealthmonth.org/
  2. https://en.m.wikipedia.org/wiki/International_Men%27s_Health_Week
  3. https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21834
  4. https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/cancer-facts/cancer-facts-for-men.html

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

13.12.2024

Saad Ullah Akram Appointed as CEO of MVision AI

Helsinki, Finland – MVision AI, a leading provider of AI-powered solutions for radiation therapy treatment planning, announces the appointment of Saad Ullah Akram as its new Chief Executive Officer. Known for its commitment to streamlining workflows and enhancing treatment quality in cancer care, MVision AI is embarking on an exciting…

Press Releases

20.11.2024

MVision AI Ranked Among the Top 10 in Deloitte Technology Fast 50 Finland for 2024

Helsinki, Finland, 20 November 2024 – MVision AI, a leading innovator in AI-driven solutions for oncology, is proud to announce its recognition among the top ten companies in the Deloitte Technology Fast 50 Finland 2024 ranking. This prestigious award acknowledges MVision AI's rapid growth and its mission-driven advancements in making…

Press Releases

7.11.2024

Safe and Ethical AI in Radiation Oncology: Regulations and MVision’s Compliance

Technology is evolving, and the same applies to Radiation Oncology. New ways and new tools require new rules. Artificial intelligence (AI)  brings tremendous potential, so the world has to learn how to get the best of it, safely.  Al systems identified as high-risk have to comply with strict requirements, including…

Articles